SCHEMBL16296178

SCHEMBL16296178

O=C(O)c1ncsc1NS(=O)(=O)c1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
PGR P06401 1/20 0.44
KDM1A O60341 1/20 0.43
MAOA P21397 1/20 0.43
KDM4E B2RXH2 1/20 0.43
SLC40A1 Q9NP59 1/20 0.43
PKM P14618 1/20 0.43
EDNRA P25101 2/20 0.42
EDNRB P24530 1/20 0.42
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
HTT P42858 1/20 0.41
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30560873 1.00 ALDH1A1 (0.47) ALDH1A1PGRKDM1AMAOAKDM4E
SCHEMBL16295214 0.85 GAA (0.46) ALDH1A1KDM4ESLC40A1PKMSLC1A3
SCHEMBL30560821 0.84 KDM4E (0.43) KDM4ETSHR
SCHEMBL16296153 0.84 KDM4E (0.43) KDM4ETSHR
SCHEMBL18065846 0.83 KDM4E (0.49) KDM4EEDNRAEDNRB
SCHEMBL16295799 0.81 KMT2A (0.49) ALDH1A1KDM4EPKM
SCHEMBL16295702 0.81 MEN1 (0.56) ALDH1A1KDM1ASLC40A1
SCHEMBL16295774 0.81 SLC40A1 (0.46) ALDH1A1SLC40A1PKM
SCHEMBL30560818 0.81 SLC40A1 (0.46) ALDH1A1SLC40A1PKM
SCHEMBL30560893 0.81 MEN1 (0.56) ALDH1A1KDM1ASLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 EP claimed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 US claimed
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ANTABIO SAS (FR) 2016-09-22 US claimed
EP-3008045-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS Antabio SAS (FR) 2016-04-20 EP claimed
WO-2014198849-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2014-12-18 WO claimed
US-12378244-B2 Diazabicyclooctanones as inhibitors of serine β-lactamases ANTABIO SAS (FR) 2025-08-05 US disclosed
US-20240391919-A1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES ANTABIO SAS (FR) 2024-11-28 US disclosed
US-11905286-B2 Diazabicyclooctanones as inhibitors of serine beta-lactamases ANTABIO SAS (FR) 2024-02-20 US disclosed
CN-117384155-A Diazabicyclooctanones as serine beta-lactamase inhibitors 安塔比奥公司 2024-01-12 CN disclosed
EP-4272831-A2 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES Antabio SAS (FR) 2023-11-08 EP disclosed
CN-111954671-B Diazabicyclooctanones as serine beta-lactamase inhibitors 安塔比奥公司 2023-09-01 CN disclosed
EP-3833665-B1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES ANTABIO SAS (FR) 2023-07-19 EP disclosed
EP-3833665-A1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES Antabio SAS (FR) 2021-06-16 EP disclosed
CN-111954671-A Diazabicyclooctanones as serine beta-lactamase inhibitors 安塔比奥公司 2020-11-17 CN disclosed
WO-2020030761-A1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES ANTABIO SAS (FR) 2020-02-13 WO disclosed
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 EP disclosed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 US disclosed
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ANTABIO SAS (FR) 2016-09-22 US disclosed
EP-3008045-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS Antabio SAS (FR) 2016-04-20 EP disclosed
WO-2014198849-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2014-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11905286-B2 Diazabicyclooctanones as inhibitors of serine beta-lactamases STS, BCKDK, PEPD ALDH1A1 650/4885PGR 4648/4885KDM1A 770/4885
US-20240391919-A1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES STS, BCKDK, PEPD ALDH1A1 650/4885PGR 4648/4885KDM1A 770/4885
US-12378244-B2 Diazabicyclooctanones as inhibitors of serine β-lactamases STS, PEPD, BCKDK ALDH1A1 669/4885PGR 4620/4885KDM1A 697/4885
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ME1, TALDO1, COASY ALDH1A1 40/4885PGR 3695/4885KDM1A 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.